Childhood Type Dermatomyositis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

ADM MCID: CHL028 MIFTS: 61	Childhood Type Dermatomyositis (ADM) Categories: Bone diseases, Immune diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Childhood Type Dermatomyositis

MalaCards integrated aliases for Childhood Type Dermatomyositis:

Name: Childhood Type Dermatomyositis ¹¹ ¹⁴ ³³

Juvenile Dermatomyositis ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ¹⁶ ⁷¹ ³¹ ³³

Juvenile Dm ¹⁹ ⁵⁸

Dermatomyositis, Childhood Type ⁷¹

Dermatomyositis Sine Myositis ¹⁹

Amyopathic Dermatomyositis ¹⁹

Childhood Dermatomyositis ¹¹

Adm ¹⁹

Characteristics:

Prevelance:

Juvenile Dermatomyositis: 1-9/1000000 (Worldwide) ⁵⁸

Age Of Onset:

Juvenile Dermatomyositis: Adolescent,Childhood,Infancy ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Immune diseases Neuronal diseases Nephrological diseases Respiratory diseases Bone diseases Skin diseases Muscle diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Diseases of the musculoskeletal system and connective tissue

Systemic connective tissue disorders

Dermatopolymyositis

Juvenile dermatomyositis

ICD11: ³³

Diseases of the immune system

Nonorgan specific systemic autoimmune disorders

Idiopathic inflammatory myopathy

Dermatomyositis

Juvenile dermatomyositis

Orphanet: ⁵⁸

Rare neurological diseases

Rare renal diseases

Rare respiratory diseases

Rare systemic and rhumatological diseases

Rare skin diseases

External Ids:

Disease Ontology ¹¹ DOID:14203

MeSH ⁴³ D003882

NCIt ⁴⁹ C27576

SNOMED-CT ⁶⁸ 1212005

ICD10 ³¹ M33.0

MESH via Orphanet ⁴⁴ C538250

ICD10 via Orphanet ³² M33.0

UMLS via Orphanet ⁷² C0263666 C2931785

Orphanet ⁵⁸ ORPHA93672

EFO ¹⁶ EFO_0000557

ICD11 ³³ 1428089375

UMLS ⁷¹ C0263666 C2931785

Sources

Summaries for Childhood Type Dermatomyositis

GARD: ¹⁹ Juvenile dermatomyositis has some similarities to adult dermatomyositis and polymyositis. Children with Juvenile dermatomyositis may have difficulty swallowing and breathing, and the heart may also be affected. About 20 to 30 percent of children with Juvenile dermatomyositis develop calcium deposits in the soft tissue. Affected children may not show higher than normal levels of the muscle enzyme creatine kinase in their blood but have higher than normal levels of other muscle enzymes.

MalaCards based summary: Childhood Type Dermatomyositis, also known as juvenile dermatomyositis, is related to interstitial lung disease and cardiovascular system disease. An important gene associated with Childhood Type Dermatomyositis is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Pirfenidone and Abatacept have been mentioned in the context of this disorder. Affiliated tissues include skin, skeletal muscle and bone, and related phenotypes are muscle weakness and fatigue

Orphanet: ⁵⁸ An early-onset form of dermatomyositis (DM), a systemic, autoimmune inflammatory muscle disorder with vasculopathy, characterized by proximal and symmetrical muscle weakness, evocative skin lesions, and systemic manifestations. Vasculopathy occurs in the skin, muscle (mainly in the perifascicular area), and sometimes in the intestinal tissue.

Wikipedia: ⁷⁵ Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy (IMM) of presumed autoimmune... more...

Sources

Related Diseases for Childhood Type Dermatomyositis

Diseases related to Childhood Type Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 849)

#	Related Disease	Score	Top Affiliating Genes
1	interstitial lung disease	31.9	TNF IFIH1 ICOSLG CCR6
2	cardiovascular system disease	31.5	TNF MIR10A ICOSLG HMGCR CCR6
3	respiratory failure	31.0	TNF IFNA1 CD4 CCR6
4	nonspecific interstitial pneumonia	30.9	TRIM21 IFIH1 EXOSC10 CD4 CCR6
5	calcinosis	30.9	TNF HLA-DRB1 HLA-DQA1
6	lupus erythematosus	30.7	TRIM21 SNRNP70 MX1 IFIH1 CCR6
7	exanthem	30.6	TRIM33 TRIM21 TNF MORC3 IFNA1 IFIH1
8	telangiectasis	30.6	TRIM21 TNF SNRNP70 EXOSC10 CCR6
9	myocarditis	30.5	TNF IFNA1 IFIH1 CD4
10	cutaneous lupus erythematosus	30.5	TRIM21 MX1 IFNA1 IFIH1 ICOSLG CCR6
11	myositis	30.4	TRIM33 TRIM21 TNF SAE1 NT5C1A IFNA1
12	collagen disease	30.3	TRIM21 SNRNP70 EXOSC10 CCR6
13	human cytomegalovirus infection	30.3	TNF CD4 CCR6
14	pneumocystosis	30.3	TNF CD4 CCR6
15	autoimmune vasculitis	30.3	TNF CD4 CCR6
16	cellulitis	30.3	TNF CD4 CCR6
17	cholangitis	30.3	TNF HLA-DRB1 HLA-DQA1
18	neuromyelitis optica	30.3	IFNA1 HLA-DRB1 HLA-DQA1
19	nocardiosis	30.2	TNF CD4
20	lymphoma, mucosa-associated lymphoid type	30.2	ICOSLG CXCR5 CD4 CCR6
21	crescentic glomerulonephritis	30.2	TNF ICOSLG CD4 CCR6
22	macs syndrome	30.2	TNF IFNA1 CD4
23	sclerosing cholangitis	30.2	TNF ICOSLG CD4 CCR6
24	leukemia, chronic myeloid	30.2	MIR10A IFNA1 ICOSLG CD4 CCR6
25	lymphatic system disease	30.2	MIR10A ICOSLG CD4 CCR6
26	aphthous stomatitis	30.2	TRIM21 TNF CD4 CCR6
27	dyskinesia of esophagus	30.2	TRIM21 SNRNP70 EXOSC10
28	myopathy	30.2	TRIM33 TRIM21 TNF SNRNP70 MORC3 MIR10A
29	autoimmune gastritis	30.2	ICOSLG CD4 CCR6
30	severe acute respiratory syndrome	30.1	TNF MX1 IFNA1 IFIH1
31	t cell deficiency	30.1	ICOSLG CD4 CCR6
32	pernicious anemia	30.1	ICOSLG CD4 CCR6
33	thyroiditis	30.1	TNF IFNA1 HLA-DRB1 HLA-DQA1
34	hemophagocytic lymphohistiocytosis	30.1	TNF CD4 CCR6
35	thrombocytopenia due to platelet alloimmunization	30.1	ICOSLG CD4 CCR6
36	autoimmune peripheral neuropathy	30.1	ICOSLG CD4
37	localized scleroderma	30.1	TNF SNRNP70 EXOSC10 CD4
38	leukemia, acute myeloid	30.1	TNF MIR10A IFNA1 ICOSLG CD4 CCR6
39	lyme disease	30.1	TNF IFNA1 HLA-DRB1
40	type 1 diabetes mellitus	30.1	TNF ICOSLG HLA-DRB1 HLA-DQA1 CCR6
41	muscular disease	30.1	TRIM33 TNF MORC3 MIR10A IFIH1 ICOSLG
42	hyper ige syndrome	30.1	ICOSLG CD4 CCR6
43	mixed connective tissue disease	30.0	TNF SNRNP70 HLA-DRB1 HLA-DQA1
44	severe cutaneous adverse reaction	30.0	TNF HLA-DRB1 CD4 CCR6
45	autoimmune disease	30.0	TRIM21 TNF IFNA1 ICOSLG HLA-DRB1 HLA-DQA1
46	urinary tract infection	30.0	TNF CD4 CCR6
47	herpes zoster	30.0	IFNA1 HLA-DRB1 CD4 CCR6
48	intestinal perforation	30.0	TNF CD4 CCR6
49	deficiency anemia	30.0	TNF IFNA1 ICOSLG CD4 CCR6
50	connective tissue disease	30.0	TRIM21 TNF SNRNP70 MIR10A IFNA1 ICOSLG

Graphical network of the top 20 diseases related to Childhood Type Dermatomyositis:

Sources

Symptoms & Phenotypes for Childhood Type Dermatomyositis

Human phenotypes related to Childhood Type Dermatomyositis:

⁵⁸ ³⁰ (show all 46)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	muscle weakness ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001324
2	fatigue ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0012378
3	dry skin ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000958
4	autoimmunity ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002960
5	elevated circulating creatine kinase concentration ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0003236
6	palpebral edema ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0100540
7	myalgia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0003326
8	mucosal telangiectasiae ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0100579
9	telangiectasia of the skin ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0100585
10	erythema ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0010783
11	skin rash ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000988
12	myositis ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0100614
13	elevated erythrocyte sedimentation rate ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0003565
14	calcinosis ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0003761
15	elevated circulating c-reactive protein concentration ³⁰	Hallmark (90%)		HP:0011227
16	constipation ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002019
17	hypotonia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001252
18	arthritis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001369
19	fever ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001945
20	alopecia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001596
21	skin ulcer ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0200042
22	arthralgia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002829
23	vasculitis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002633
24	cutaneous photosensitivity ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000992
25	pruritus ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000989
26	restrictive ventilatory defect ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002091
27	poikiloderma ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001029
28	muscle spasm ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0003394
29	dysarthria ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001260
30	dysphonia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001618
31	dysphagia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002015
32	emg abnormality ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003457
33	angina pectoris ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001681
34	abdominal pain ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002027
35	dyspnea ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002094
36	arrhythmia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0011675
37	bundle branch block ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0011710
38	cough ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0012735
39	gastrointestinal hemorrhage ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002239
40	hoarse voice ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001609
41	pericarditis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001701
42	weight loss ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001824
43	limitation of joint mobility ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001376
44	cardiomyopathy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001638
45	pulmonary fibrosis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002206
46	elevated c-reactive protein level ⁵⁸		Very frequent (99-80%)

MGI Mouse Phenotypes related to Childhood Type Dermatomyositis:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	immune system	MP:0005387	9.4	CCR6 CD4 CXCR5 HLA-DQA1 ICOSLG IFIH1

Sources

Drugs & Therapeutics for Childhood Type Dermatomyositis

Drugs for Childhood Type Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Pirfenidone

Approved, Investigational

Phase 4

53179-13-8

40632

Abatacept

Approved

Phase 4

332348-12-6

Antirheumatic Agents

Phase 4

Anti-Inflammatory Agents

Phase 4

Vaccines

Phase 4

Analgesics

Phase 4

Anti-Inflammatory Agents, Non-Steroidal

Phase 4

Analgesics, Non-Narcotic

Phase 4

Immune Checkpoint Inhibitors

Phase 4

Hormones

Phase 4

Hormone Antagonists

Phase 4

Melanocyte-Stimulating Hormones

Phase 4

Adrenocorticotropic Hormone

Phase 4

beta-Endorphin

Phase 4

Prednisolone phosphate

Approved, Vet_approved

Phase 3

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 3

52-21-1

Prednisolone

Approved, Vet_approved

Phase 3

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 3

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 3

83-43-2

4159 6741

Prednisone

Approved, Vet_approved

Phase 3

53-03-2

5865

Prednisolone hemisuccinate

Experimental

Phase 3

2920-86-7

4897

Methylprednisolone Acetate

Phase 3

584547

Cyclosporins

Phase 3

Basiliximab

Approved, Investigational

Phase 2

179045-86-4

Tacrolimus

Approved, Investigational

Phase 2

104987-11-3

6473866 445643

Rituximab

Approved

Phase 2

174722-31-7

Levoleucovorin

Approved, Experimental, Investigational

Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Methotrexate

Approved

Phase 2

1959-05-2, 59-05-2

4112 126941

Mycophenolic acid

Approved, Investigational

Phase 2

24280-93-1

446541

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2

59-30-3

6037

Calcineurin Inhibitors

Phase 2

Antineoplastic Agents, Hormonal

Phase 2

Neuroprotective Agents

Phase 2

Antiemetics

Phase 2

glucocorticoids

Phase 2

Gastrointestinal Agents

Phase 2

Protective Agents

Phase 2

Antidotes

Phase 2

Sodium thiosulfate

Phase 2

Pharmaceutical Solutions

Phase 2

Antioxidants

Phase 2

Chelating Agents

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Immunosuppressive Agents

Phase 2

Immunologic Factors

Phase 2

Folate

Phase 2

Vitamin B9

Phase 2

Anti-Bacterial Agents

Phase 2

Anti-Infective Agents

Phase 2

Antitubercular Agents

Phase 2

Interventional clinical trials:

(show all 24)

#	Name	Status	NCT ID	Phase	Drugs
1	Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases	Unknown status	NCT01151644	Phase 4
2	Randomized Controlled Trial of Pirfenidone in Patients With Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis	Unknown status	NCT02821689	Phase 4	Pirfenidone
3	Abatacept for the Treatment of Refractory Juvenile Dermatomyositis	Completed	NCT02594735	Phase 4	Abatacept
4	Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis	Completed	NCT02245841	Phase 4	H.P. Acthar Gel
5	Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease	Completed	NCT00815282	Phase 4
6	Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate	Completed	NCT00323960	Phase 3	3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
7	Basiliximab as a Treatment of Interstitial Pneumonia in Clinical Amyopathic Dermatomyositis Patients	Unknown status	NCT03192657	Phase 2	Basiliximab;Calcineurin Inhibitors;Steroids
8	Phase II Study of Prednisolone/Methylprednisolone Absorption in Children With Juvenile Dermatomyositis	Completed	NCT00004357	Phase 2	Methylprednisolone;Prednisolone
9	Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis	Completed	NCT01572844	Phase 2	Sodium thiosulfate
10	Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM)	Completed	NCT00106184	Phase 2	Rituximab;Placebo
11	Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis	Recruiting	NCT05524311	Phase 2	Baricitinib
12	Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01)	Recruiting	NCT05000216	Phase 2	Continue IS (MMF or MPA);Continue IS (MTX);Withhold IS (MMF or MPA);Withhold IS (MTX);Withhold IS (B cell depletion therapy)
13	Efficacy and Safety of Creatine Supplementation in Patients With Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis	Unknown status	NCT01217320
14	Incidence and Prevalence of Juvenile Dermatomyositis in Alsace Between 2000 to 2015	Unknown status	NCT03432455
15	Retrospective Descriptive Study of Juvenile Dermatomyositis in Alsace	Unknown status	NCT03433638
16	Clinical Analysis of 12 Cases of Juvenile Dermatomyositis Treated With Methylprednisolone Repeated Intermittent Pulse Combined With Mycophenolate Mofetil	Completed	NCT05509140
17	The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis	Completed	NCT02267005
18	The CARRA Registry	Completed	NCT01697254
19	Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area	Completed	NCT03430388
20	Studies of Natural History, Pathogenesis, and Outcomes in Autoimmune and Inflammatory Diseases Including Juvenile Dermatomyositis	Recruiting	NCT00059748
21	Environmental Risk Factors for the Anti-Synthetase Syndrome	Recruiting	NCT01276470
22	Correlation Between the Change of Peripheral Lymphocyte Subsets and Clinically Amyopathic Dermatomyositis Combined With Rapidly Progressive Interstitial Lung Disease	Recruiting	NCT04613219		Tofacitinib 5 MG [Xeljanz]
23	TRACER: Transition to Adulthood Through Coaching and Empowerment in Rheumatology, A Feasibility Study	Not yet recruiting	NCT05545839
24	Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis	No longer available	NCT01724580		Baricitinib

Search NIH Clinical Center for Childhood Type Dermatomyositis

Sources

Genetic Tests for Childhood Type Dermatomyositis

Sources

Anatomical Context for Childhood Type Dermatomyositis

Organs/tissues related to Childhood Type Dermatomyositis:

MalaCards : Skin, Skeletal Muscle, Bone, Heart, Lung, T Cells, Endothelial

Sources

Publications for Childhood Type Dermatomyositis

Articles related to Childhood Type Dermatomyositis:

(show top 50) (show all 1978)

#	Title	Authors	PMID	Year
1	The clinical features of juvenile dermatomyositis: A single-centre inception cohort. ⁶²	Cancarini P...Feldman BM	36183479	2022
2	Cardiac involvement in anti-MDA5 dermatomyositis: a case-based review. ⁶²	Quintero-Gonzalez DC...Munoz-Vahos CH	36454342	2022
3	Mechanic Hands/Hiker Feet in a Patient With Amyopathic Dermatomyositis and Interstitial Lung Disease. ⁶²	Regmi A...Speiser JJ	36395446	2022
4	[[Translated article]]Juvenile Dermatomyositis During the SARS-CoV-2 Pandemic: Acral and Oral Mucosal Involvement. ⁶²	Giacaman A...Martin-Santiago A	36464006	2022
5	Use of Adalimumab in a Child with Juvenile Dermatomyositis and Calcinosis. ⁶²	Jin J...Yu H	36324016	2022
6	[Chinese guidelines for the diagnosis and treatment of juvenile dermatomyositis]. ⁶²	Subspecialty Group of Immunology, the Society of Pediatrics, Chinese Medical Association...Chinese Alliance of Pediatric Rheumatic and Immunologic Diseases	36444423	2022
7	Palmar erythema: A diagnostic clue of juvenile dermatomyositis. ⁶²	Amoroso S...Taddio A	36468501	2022
8	Assessment of Thigh MRI Radiomics and Clinical Characteristics for Assisting in Discrimination of Juvenile Dermatomyositis. ⁶²	Hu M...Xu X	36431189	2022
9	Bisphosphonate therapy for juvenile dermatomyositis-associated calcinosis and metaphyseal zebra lines. ⁶²	Janarthanan M...Murali A	36343985	2022
10	Early-onset juvenile dermatomyositis: A tertiary referral center experience and review of the literature. ⁶²	Sener S...Ozen S	36434896	2022
11	Two Distinct Immune Cell Signatures Predict the Clinical Outcomes in Patients With Amyopathic Dermatomyositis With Interstitial Lung Disease. ⁶²	Ye Y...Zhang X	35713981	2022
12	Anti-MDA5 antibody-associated clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease. ⁶²	Horino T...Terada Y	36108903	2022
13	A case of clinically amyopathic dermatomyositis in a Filipino woman. ⁶²	Amadore RA...Natividad TEL	36184686	2022
14	Melanoma differentiation-associated gene 5 amyopathic dermatomyositis following an acute Mycoplasma pneumoniae infection: a case report. ⁶²	Hoey J...Nusbaum J	36316755	2022
15	Obesity as a comorbidity in children and adolescents with autoimmune rheumatic diseases. ⁶²	Held M...Jelusic M	36394598	2022
16	Early Abnormal Nailfold Capillary Changes Are Predictive of Calcinosis Development in Juvenile Dermatomyositis. ⁶²	Nozawa T...Feldman BM	35914785	2022
17	Linear morphea with overlying lichen sclerosus and calcinosis cutis associated with juvenile dermatomyositis. ⁶²	Kaur M...Alam A	36384242	2022
18	Therapeutic plasma exchange for steroid refractory idiopathic inflammatory myopathies with interstitial lung disease. ⁶²	Thompson TZ...Winters JL	36408807	2022
19	Hepatic veno-occlusive disease accompanied by thrombotic microangiopathy developing during treatment of juvenile dermatomyositis and macrophage activation syndrome: A case report. ⁶²	Mouri M...Mori M	36416547	2022
20	Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study. ⁶²	Dabbak I...Bader-Meunier B	35199139	2022
21	Juvenile Dermatomyositis: what comes next? Long-term outcomes in childhood myositis from a patient perspective. ⁶²	Boros C...JDM Cohort and Biomarker Study (JDCBS)	36384526	2022
22	Anti-Valosin-Containing Protein (VCP/p97) Autoantibodies in Inclusion Body Myositis and Other Inflammatory Myopathies. ⁶²	Amlani A...Fritzler MJ	36373433	2022
23	Calcified dyspigmented plaques, discharging sinuses and guttate hypopigmentation: An unusual clinical presentation of clinically amyopathic dermatomyositis. ⁶²	Kharghoria G...Gupta V	36332085	2022
24	Juvenile dermatomyositis associated with autoantibodies to small ubiquitin-like modifier activating enzyme: a report of 4 cases from North India and a review of literature. ⁶²	Vignesh P...Singh S	36278969	2022
25	Challenges in diagnosing COVID-19 related disease in pediatric patients with rheumatic disease. ⁶²	Sener S...Ozen S	34850910	2022
26	Chemotherapy induced juvenile dermatomyositis: a novel presentation- a case report. ⁶²	Vagha K...Vagha J	36316673	2022
27	Assessment of the outcomes of SARS-CoV-2 infection in children and young people followed at Portuguese pediatric rheumatology clinics. ⁶²	Melo AT...Ramos FO	36056926	2022
28	Masseter idiopathic calcinosis circumscripta: A rare condition. ⁶²	Skhiri W...Salem R	35235881	2022
29	Juvenile dermatomyositis-associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy. ⁶²	Agud-Dios M...Perez SIP	36286617	2022
30	Spontaneous pneumomediastinum, a rare manifestation of clinically amyopathic dermatomyositis. ⁶²	Lucas Rocha M...C Branco J	36057086	2022
31	Whole-body MR imaging in evaluation of children with juvenile dermatomyositis. ⁶²	Sreelal Tv...Sodhi KS	35998441	2022
32	Clinically amyopathic dermatomyositis with diffuse erosive erythema in a patient with anti-small ubiquitin-like modifier activating enzyme antibody. ⁶²	Hiraiwa T...Yamamoto T	35106751	2022
33	Comment on: Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis. ⁶²	Mutoh T...Fujii H	36218414	2022
34	Clinical features and immune-related protein patterns of anti-MDA5 positive clinically amyopathic dermatomyositis Dutch patients. ⁶²	Hensgens MPM...Leavis HL	35048953	2022
35	Does the BNT162b2 Vaccine Trigger Antimelanoma Differentiation-Associated Gene 5 Antibody-Positive Interstitial Lung Disease? ⁶²	Mutoh T...Kudo M	36182114	2022
36	COVID-19 quarantine in adolescents with autoimmune rheumatic diseases: mental health issues and life conditions. ⁶²	Ihara BP...Campos LMMA	35701628	2022
37	Onset of amyopathic dermatomyositis following mRNA-based SARS-CoV-2 vaccination. ⁶²	Kreuter A...Michalowitz AL	35536636	2022
38	Satisfactory Response to Pulsed Dye Laser Treatment of Facial Erythema in a Patient with Amyopathic Dermatomyositis. ⁶²	Naranjo Diaz MJ...Ruiz-Villaverde R	36115383	2022
39	Correction: Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review. ⁶²	Nishi K...Ito S	36064710	2022
40	Preclinical ocular microvascular changes in juvenile dermatomyositis: A pilot optical coherence tomography angiography study. ⁶²	Yilmaz Tugan B...Karabas L	35605694	2022
41	Juvenile Dermatomyositis With Macrophage Activation and Severe Encephalopathy. ⁶²	Jagwani H...Pal P	36101954	2022
42	Adult and juvenile dermatomyositis treatment. ⁶²	Patil A...Goldust M	36065712	2022
43	Calcinosis cutis with amyopathic dermatomyositis. ⁶²	Samanta J...Jain S	35731215	2022
44	A case of juvenile amyopathic dermatomyositis with anti-transcription intermediary factor 1-α antibody showing negative anti-TIF1-γ ELISA results: Comment on "Case of pembrolizumab-induced dermatomyositis with anti-transcription intermediary factor 1-γ antibody". ⁶²	Koizumi H...Akiyama M	36176040	2022
45	Epidemiology conduction of paediatric rheumatic diseases based on the registry database of the Pediatric Rheumatology Association of Japan. ⁶²	Narazaki H...Yokoyama K	36112493	2022
46	[Lack of therapeutic response: Is it really a rheumatoid Arthritis?] ⁶²	Marinoska T...Schwarting A	36030790	2022
47	Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital. ⁶²	Suga T...Iwamoto Y	35399148	2022
48	Performance of the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria in Patients With Idiopathic Inflammatory Myopathy and Anti-Melanoma Differentiation-Associated Protein 5 Positivity. ⁶²	So H...Tam LS	35467787	2022
49	A Systematic Review and Metaanalysis of Predictors of Mortality in Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease. ⁶²	Hannah J...Gordon P	36379584	2022
50	Genetic analysis for type 1 diabetes genes in juvenile dermatomyositis unveils genetic disease overlap. ⁶²	Qu HQ...Hakonarson H	35171267	2022

Sources

Genes for Childhood Type Dermatomyositis

Genes related to Childhood Type Dermatomyositis (0 elite genes):

(show all 26)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	10.68	DISEASES inferred ¹⁴ ¹⁴
2	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	8.69	DISEASES inferred ¹⁴ ¹⁴
3	MORC3	MORC Family CW-Type Zinc Finger 3	Protein Coding	8.35	DISEASES inferred ¹⁴
4	TRIM33	Tripartite Motif Containing 33	Protein Coding	7.64	DISEASES inferred ¹⁴
5	IFIH1	Interferon Induced With Helicase C Domain 1	Protein Coding	7.57	DISEASES inferred ¹⁴
6	EXOSC10	Exosome Component 10	Protein Coding	6.99	DISEASES inferred ¹⁴
7	MIR10A	MicroRNA 10a	RNA Gene	6.81	DISEASES inferred ¹⁴ ¹⁴
8	TRIM24	Tripartite Motif Containing 24	Protein Coding	6.63	DISEASES inferred ¹⁴
9	TRIM21	Tripartite Motif Containing 21	Protein Coding	6.4	DISEASES inferred ¹⁴
10	HLA-DQA1	Major Histocompatibility Complex, Class II, DQ Alpha 1	Protein Coding	6.38	DISEASES inferred ¹⁴
11	CXCR5	C-X-C Motif Chemokine Receptor 5	Protein Coding	6.22	DISEASES inferred ¹⁴
12	SNRNP70	Small Nuclear Ribonucleoprotein U1 Subunit 70	Protein Coding	6.22	DISEASES inferred ¹⁴
13	MX1	MX Dynamin Like GTPase 1	Protein Coding	6.08	DISEASES inferred ¹⁴
14	NT5C1A	5'-Nucleotidase, Cytosolic IA	Protein Coding	6.08	DISEASES inferred ¹⁴
15	TNF	Tumor Necrosis Factor	Protein Coding	6.05	DISEASES inferred ¹⁴
16	IFNA1	Interferon Alpha 1	Protein Coding	6.01	DISEASES inferred ¹⁴
17	HMGCR	3-Hydroxy-3-Methylglutaryl-CoA Reductase	Protein Coding	5.85	DISEASES inferred ¹⁴
18	CD4	CD4 Molecule	Protein Coding	5.82	DISEASES inferred ¹⁴
19	SAE1	SUMO1 Activating Enzyme Subunit 1	Protein Coding	5.79	DISEASES inferred ¹⁴
20	HLA-DRB1	Major Histocompatibility Complex, Class II, DR Beta 1	Protein Coding	5.77	DISEASES inferred ¹⁴
21	HARS1	Histidyl-TRNA Synthetase 1	Protein Coding	5.74	DISEASES inferred ¹⁴
22	CXCL10	C-X-C Motif Chemokine Ligand 10	Protein Coding	5.7	DISEASES inferred ¹⁴
23	PIK3C2A	Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Alpha	Protein Coding	5.65	DISEASES inferred ¹⁴
24	RO60	Ro60, Y RNA Binding Protein	Protein Coding	5.62	DISEASES inferred ¹⁴
25	PLCL1	Phospholipase C Like 1 (Inactive)	Protein Coding	5.61	DISEASES inferred ¹⁴
26	IFI44L	Interferon Induced Protein 44 Like	Protein Coding	5.6	DISEASES inferred ¹⁴

Sources

Variations for Childhood Type Dermatomyositis

Sources

Expression for Childhood Type Dermatomyositis

Genes differentially expressed in tissues of Childhood Type Dermatomyositis patients vs. healthy controls: ³⁵ (show all 35)

#	Gene	Description	Tissue	Up/Dn	Fold Change (log2)
1	IFIT3	interferon induced protein with tetratricopeptide repeats 3	Skeletal Muscle	+	5.58
2	ISG15	ISG15 ubiquitin like modifier	Skeletal Muscle	+	5.25
3	XIST	X inactive specific transcript	Skeletal Muscle	+	5.14
4	RSAD2	radical S-adenosyl methionine domain containing 2	Skeletal Muscle	+	4.94
5	GBP1	guanylate binding protein 1	Skeletal Muscle	+	4.88
6	CMPK2	cytidine/uridine monophosphate kinase 2	Skeletal Muscle	+	4.61
7	IFI44L	interferon induced protein 44 like	Skeletal Muscle	+	4.42
8	MX1	MX dynamin like GTPase 1	Skeletal Muscle	+	4.40
9	IFI44	interferon induced protein 44	Skeletal Muscle	+	4.34
10	IFIT2	interferon induced protein with tetratricopeptide repeats 2	Skeletal Muscle	+	3.96
11	IFI27	interferon alpha inducible protein 27	Skeletal Muscle	+	3.86
12	CXCL11	C-X-C motif chemokine ligand 11	Skeletal Muscle	+	3.67
13	RPS4Y1	ribosomal protein S4 Y-linked 1	Skeletal Muscle	-	3.57
14	IFIT1	interferon induced protein with tetratricopeptide repeats 1	Skeletal Muscle	+	3.57
15	MYH3	myosin heavy chain 3	Skeletal Muscle	+	3.54
16	SAMHD1	SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1	Skeletal Muscle	+	3.52
17	XAF1	XIAP associated factor 1	Skeletal Muscle	+	3.44
18	KLHDC7B	kelch domain containing 7B	Skeletal Muscle	+	3.44
19	IFI6	interferon alpha inducible protein 6	Skeletal Muscle	+	3.43
20	IFIH1	interferon induced with helicase C domain 1	Skeletal Muscle	+	3.43
21	PARP12	poly(ADP-ribose) polymerase family member 12	Skeletal Muscle	+	3.41
22	IFI16	interferon gamma inducible protein 16	Skeletal Muscle	+	3.40
23	PLSCR1	phospholipid scramblase 1	Skeletal Muscle	+	3.37
24	STAT1	signal transducer and activator of transcription 1	Skeletal Muscle	+	3.37
25	PSMB8	proteasome 20S subunit beta 8	Skeletal Muscle	+	3.35
26	NNMT	nicotinamide N-methyltransferase	Skeletal Muscle	+	3.31
27	TRIM22	tripartite motif containing 22	Skeletal Muscle	+	3.27
28	DTX3L	deltex E3 ubiquitin ligase 3L	Skeletal Muscle	+	3.23
29	EIF2AK2	eukaryotic translation initiation factor 2 alpha kinase 2	Skeletal Muscle	+	3.14
30	IRF7	interferon regulatory factor 7	Skeletal Muscle	+	3.13
31	OAS1	2'-5'-oligoadenylate synthetase 1	Skeletal Muscle	+	3.09
32	IFITM1	interferon induced transmembrane protein 1	Skeletal Muscle	+	3.06
33	TNFSF10	TNF superfamily member 10	Skeletal Muscle	+	3.05
34	PARP9	poly(ADP-ribose) polymerase family member 9	Skeletal Muscle	+	3.05
35	POSTN	periostin	Skeletal Muscle	+	3.03

Search GEO for disease gene expression data for Childhood Type Dermatomyositis.

Sources

Pathways for Childhood Type Dermatomyositis

Pathways related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

(show all 11)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.75	TRIM21 TNF MX1 IFNA1 IFIH1 ICOSLG
2	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.03	CD4 HLA-DQA1 HLA-DRB1 IFNA1 MX1 TNF
3	Interferon gamma signaling ⁶⁶ Show member pathways Interferon Signaling ⁶⁶ Regulation of IFNG signaling ⁶⁶	12.21	TRIM21 MX1 IFNA1 HLA-DRB1 HLA-DQA1
4	CD28 co-stimulation ⁶⁶ Show member pathways Activation of AKT2 ⁶⁶ CD28 dependent PI3K/Akt signaling ⁶⁶ CD28 dependent Vav1 pathway ⁶⁶ Costimulation by the CD28 family ⁶⁶ CTLA4 Signaling ⁶⁴ VEGFR2 mediated vascular permeability ⁶⁶	12.14	ICOSLG HLA-DRB1 HLA-DQA1 CD4
5	CD28 Signaling in T-Helper Cell ⁶⁴ Show member pathways ICos-ICosL Pathway in T-Helper Cell ⁶⁴	11.94	ICOSLG HLA-DRB1 HLA-DQA1 CD4
6	Phosphorylation of CD3 and TCR zeta chains ⁶⁶ Show member pathways Generation of second messenger molecules ⁶⁶ PD-1 signaling ⁶⁶	11.55	HLA-DRB1 HLA-DQA1 CD4
7	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.46	TNF ICOSLG CXCR5
8	Allograft rejection ⁷⁴	11.23	TNF HLA-DRB1 HLA-DQA1 CXCR5
9	THC Differentiation Pathway ⁶⁴	11.16	TNF HLA-DRB1 HLA-DQA1 CD4
10	Innate Lymphoid Cells Differentiation ⁶⁵	10.83	TNF CXCR5 CD4 CCR6
11	Cytokines and inflammatory response ⁷⁴	10.79	TNF HLA-DRB1 CD4

Sources

GO Terms for Childhood Type Dermatomyositis

Cellular components related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	external side of plasma membrane	GO:0009897	9.4	TNF ICOSLG HLA-DRB1 CXCR5 CD4 CCR6

Biological processes related to Childhood Type Dermatomyositis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	immune response	GO:0006955	10.14	TNF HLA-DRB1 HLA-DQA1 CXCR5 CD4 CCR6
2	negative regulation of viral genome replication	GO:0045071	9.91	TNF MX1 IFIH1
3	calcium-mediated signaling	GO:0019722	9.86	CCR6 CD4 CXCR5 TNF
4	defense response	GO:0006952	9.85	TNF MX1 IFNA1 ICOSLG
5	positive regulation of T cell activation	GO:0050870	9.8	HLA-DRB1 HLA-DQA1 CD4
6	immune system process	GO:0002376	9.7	MX1 MORC3 IFIH1 ICOSLG HLA-DRB1 HLA-DQA1
7	humoral immune response	GO:0006959	9.56	TNF IFNA1 HLA-DRB1 CCR6
8	positive regulation of viral entry into host cell	GO:0046598	9.1	TRIM21 HLA-DRB1 CD4